Literature DB >> 19264738

Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study.

James W Wheless1, Dave Clarke, Collin A Hovinga, Michelle Ellis, Misha Durmeier, Amy McGregor, Fred Perkins.   

Abstract

Intravenous antiepileptic drugs are required in patients needing urgent treatment or unable to take oral medication. The safety of intravenous levetiracetam has been established in prospective studies of adult epilepsy and healthy participants. The authors performed a prospective, single-center study to evaluate the safety of a rapid loading dose of intravenous levetiracetam. Patients were divided into 3 equal dosing groups (N = 15 each): 20, 40, and 60 mg/kg (corresponding to maximum doses of 1, 2, and 3 g). Electrocardiogram and safety assessment were performed during the infusion. Ages were 4 to 32 years. Postinfusion serum levetiracetam concentrations were 14 to 189 microg/mL. There were no significant changes in blood pressure, no local infusion site reactions, and no electrocardiogram abnormalities. The authors concluded that high serum levels of parenteral levetiracetam can be achieved rapidly and safely, in a small infusion volume. This finding has important implications for the treatment of status epilepticus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264738     DOI: 10.1177/0883073808331351

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  13 in total

1.  Levetiracetam for treatment of neonatal seizures.

Authors:  Nicholas S Abend; Ana M Gutierrez-Colina; Heather M Monk; Dennis J Dlugos; Robert R Clancy
Journal:  J Child Neurol       Date:  2011-01-13       Impact factor: 1.987

2.  Neurodevelopmental outcomes at 9-14 months gestational age after treatment of neonatal seizures due to brain injury.

Authors:  Suman Ghosh; Andrea C Cabassa Miskimen; Janet Brady; Matthew A Robinson; Baiming Zou; Michael Weiss; Peter B Kang
Journal:  Childs Nerv Syst       Date:  2019-07-05       Impact factor: 1.475

3.  Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis.

Authors:  Zhan-Miao Yi; Xu-Li Zhong; Ming-Lu Wang; Yuan Zhang; Suo-Di Zhai
Journal:  Front Pharmacol       Date:  2020-05-21       Impact factor: 5.810

4.  Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.

Authors:  Richard E Appleton; Naomi Ea Rainford; Carrol Gamble; Shrouk Messahel; Amy Humphreys; Helen Hickey; Kerry Woolfall; Louise Roper; Joanne Noblet; Elizabeth Lee; Sarah Potter; Paul Tate; Nadia Al Najjar; Anand Iyer; Vicki Evans; Mark D Lyttle
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

5.  Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.

Authors:  Abhishek G Sathe; Usha Mishra; Vijay Ivaturi; Richard C Brundage; James C Cloyd; Jordan J Elm; James M Chamberlain; Robert Silbergleit; Jaideep Kapur; Daniel H Lowenstein; Shlomo Shinnar; Hannah R Cock; Nathan B Fountain; Lynn Babcock; Lisa D Coles
Journal:  J Clin Pharmacol       Date:  2021-01-12       Impact factor: 2.860

6.  A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study.

Authors:  Stuart R Dalziel; Jeremy Furyk; Megan Bonisch; Ed Oakley; Meredith Borland; Jocelyn Neutze; Susan Donath; Cynthia Sharpe; Simon Harvey; Andrew Davidson; Simon Craig; Natalie Phillips; Shane George; Arjun Rao; Nicholas Cheng; Michael Zhang; Kam Sinn; Amit Kochar; Christine Brabyn; Franz E Babl
Journal:  BMC Pediatr       Date:  2017-06-22       Impact factor: 2.125

7.  Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial.

Authors:  Mark D Lyttle; Carrol Gamble; Shrouk Messahel; Helen Hickey; Anand Iyer; Kerry Woolfall; Amy Humphreys; Naomi E A Bacon; Louise Roper; Franz E Babl; Stuart R Dalziel; Mary Ryan; Richard E Appleton
Journal:  Trials       Date:  2017-06-19       Impact factor: 2.279

8.  Antiepileptic Drugs Impair Shortening of Isolated Cardiomyocytes.

Authors:  Johanna Hulbert; Christian E Elger; Rainer Meyer; Rainer Surges
Journal:  Front Neurol       Date:  2017-04-03       Impact factor: 4.003

9.  Levetiracetam use in the critical care setting.

Authors:  Jennifer L Dewolfe; Jerzy P Szaflarski
Journal:  Front Neurol       Date:  2013-08-23       Impact factor: 4.003

Review 10.  Clinical pharmacology and pharmacokinetics of levetiracetam.

Authors:  Chanin Wright; Jana Downing; Diana Mungall; Owais Khan; Amanda Williams; Ekokobe Fonkem; Darin Garrett; Jose Aceves; Batool Kirmani
Journal:  Front Neurol       Date:  2013-12-04       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.